Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Sangamo Therapeutics has gained a consensus rating of "Moderate Buy" from analysts, with two hold and four buy recommendations.
• The company reported a quarterly loss of ($0.08) earnings per share, falling short of the consensus estimate of ($0.07), with revenue significantly below expectations at $18.31 million.
• Sangamo's stock price opened at $0.55 and has experienced a 52-week range from $0.41 to $3.18.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $4.50.

Several equities research analysts have weighed in on the company. Wall Street Zen raised Sangamo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday. Finally, Barclays decreased their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $0.55 on Friday. The company has a market cap of $165.10 million, a PE ratio of -1.89 and a beta of 1.20. The business has a 50-day simple moving average of $0.53 and a two-hundred day simple moving average of $0.64. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%. On average, sell-side analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SGMO. Point72 Asset Management L.P. acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter worth about $2,316,000. Wasatch Advisors LP lifted its holdings in shares of Sangamo Therapeutics by 17.7% during the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company's stock worth $4,376,000 after purchasing an additional 1,215,653 shares during the period. GSA Capital Partners LLP lifted its holdings in shares of Sangamo Therapeutics by 2,962.2% during the first quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company's stock worth $634,000 after purchasing an additional 934,649 shares during the period. Two Sigma Advisers LP purchased a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $722,000. Finally, Two Sigma Investments LP raised its position in Sangamo Therapeutics by 222.1% during the fourth quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company's stock valued at $1,033,000 after acquiring an additional 698,296 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.